NRXP all time low! 2 X Phase 3 clinical trials! NRx Pharmaceuticals, Inc. (NRXP) has two Phase III assets for which it has Fast Track and Breakthrough Therapy designation, respectively: intravenous ZYESAMI® for Critical COVID-19 and NRX-101 for bipolar depression with suicidality.
52 Week Range 2.38 - 48.80.
in 2020 the stock was $77.
My price target is 16.50
If this is not the time to buy this stock, then when?!
NRX
NRXP COVID-19 Vaccine Effectiveness Against Delta VariantNRx Pharmaceuticals announced that its BriLife COVID-19 Vaccine is Effectiveness Against Delta Variant.
Information was released by Israel Institute for Biological Research.
Since the pandemic isn`t over, there is a place in the market for new developers that have effective vaccines.
I consider this a premium call, the upside i see here is 400%, or the 24usd resistance.
NRXP 52 Week Range 4.07 - 76.99usd. Now the price is 6.75usd.
Is this a buy or not?
Market Cap of only 396.97Mil
NRXP | in search for the next MRNA After a perfect touch of the .618 Fib retracement level, now NRXP is ready to aim higher!
Get ready for action!
My first price target is 35usd.
Today NRx was granted Fast Track Designation by the U.S. Food and Drug Administration for ZYESAMI (aviptadil) for the treatment of Critical COVID-19 with respiratory failure!
NRx Pharmaceuticals has also a Partnership with the Israel Institute for Biological Research to Complete Development and Commercialization of BriLife COVID Vaccine.
NRx Pharmaceuticals has Successful Commercial Formulation for ZYESAMI (aviptadil) and Stockpiling of COVID-19 Medication Subject to Regulatory Approval.
ZYESAMI Helps Prevent "Cytokine Storm" in Patients with COVID-19